HIV 및 에이즈 진단 시장 : 검사 유형별, 제품 유형, 검사 방법, 최종 사용자, 용도별 예측(2026-2032년)

The HIV or AIDS Diagnostics Market is projected to grow by USD 4.06 billion at a CAGR of 6.56% by 2032.

HIV and AIDS diagnostics remain central to global prevention, treatment initiation, viral suppression monitoring, and public health surveillance. UNAIDS reported approximately 39.9 million people living with HIV in 2023, with 1.3 million new HIV infections and 630,000 AIDS-related deaths, reinforcing the continued need for earlier, more accessible, and more accurate HIV testing.

The HIV diagnostics landscape is shaped by laboratory-based fourth-generation antigen-antibody assays, nucleic acid testing, point-of-care rapid tests, HIV self-testing, CD4 monitoring, viral load testing, and confirmatory algorithms. Demand is supported by health systems pursuing the UNAIDS 95-95-95 targets, expanding community-based screening, and integrating diagnostics into sexual health, maternal health, tuberculosis, and harm-reduction programs.

Transformative Shifts in the HIV Diagnostics Landscape

The HIV diagnostics landscape is shifting from centralized, episodic testing toward decentralized, digitally connected, and patient-centered models. WHO-backed strategies emphasize differentiated HIV testing services, including provider-initiated testing, community testing, partner services, and HIV self-testing to reach populations underserved by conventional clinics.

Technology adoption is also changing procurement and implementation priorities. Laboratories continue to rely on high-throughput immunoassay platforms and molecular systems, while public health programs are expanding rapid diagnostic tests, dried blood spot collection, and near-patient viral load solutions. Regulatory rigor, supply chain resilience, quality assurance, and assay performance across HIV-1 groups and HIV-2 remain critical competitive factors.

Cumulative Impact of Artificial Intelligence on HIV Diagnostics

Artificial intelligence is beginning to influence HIV and AIDS diagnostics through risk stratification, laboratory workflow automation, quality control, digital test reading, outbreak signal detection, epidemiological analytics, and linkage-to-care optimization. AI-enabled tools can help health systems identify testing gaps, prioritize outreach, improve appointment follow-up, and reduce delays between diagnosis and antiretroviral therapy initiation.

The impact remains cumulative rather than fully disruptive because HIV diagnosis depends on validated assays, regulated testing algorithms, and confirmatory standards. Industry leaders should treat AI as a decision-support layer that improves efficiency, data quality, and public health targeting, while maintaining clinical validation, explainability, privacy safeguards, cybersecurity controls, and compliance with FDA, WHO, IVDR, and local regulatory expectations.

Key Regional Insights Across Global HIV Diagnostics

Asia-Pacific is a high-priority region due to large populations, expanding diagnostic infrastructure, and national HIV programs in China, India, Japan, Australia, South Korea, and ASEAN markets. Regional demand is supported by hospital-based immunoassay testing, molecular platforms, antenatal screening, blood safety programs, and community outreach, while rural access, stigma, and uneven linkage to care continue to influence testing uptake.

North America remains a mature HIV diagnostics region characterized by fourth-generation laboratory testing, nucleic acid testing, PrEP-linked screening, strong public health surveillance, and guideline-led confirmatory testing. Latin America, led by Brazil and Mexico, is expanding access through public-sector procurement, community testing, and integrated HIV care pathways. Europe benefits from established laboratory networks, national screening guidelines, and EU regulatory harmonization, although late diagnosis remains a concern in parts of the region. The Middle East is shaped by centralized testing models, migrant screening, and privacy-sensitive care pathways, while Africa represents the highest public health need, with UNAIDS identifying sub-Saharan Africa as the region carrying the largest share of the global HIV burden and requiring sustained access to rapid testing, viral load monitoring, and early infant diagnosis.

Key Group Insights for HIV & AIDS Diagnostics

ASEAN markets are advancing HIV testing through national programs, donor-supported procurement, self-testing pilots, antenatal screening, and outreach to key populations, with cross-border mobility making surveillance and linkage to care important. The GCC is defined by high-income health systems, centralized laboratories, migrant health screening, premarital and occupational testing policies in some settings, and strong demand for confidential, regulated testing pathways.

The European Union is influenced by the In Vitro Diagnostic Regulation, which raises expectations for clinical evidence, performance evaluation, traceability, and post-market surveillance. BRICS countries combine large testing volumes with diverse reimbursement and procurement models, making affordability, local manufacturing capacity, scalable molecular testing, and public-sector access essential. G7 markets drive innovation in high-throughput assays, digital reporting, laboratory automation, and AI-enabled analytics, while NATO countries emphasize resilient diagnostics, military readiness, emergency preparedness, and biosurveillance interoperability.

Key Country Insights in HIV Diagnostics

The United States has a highly developed HIV diagnostics ecosystem supported by CDC testing recommendations, fourth-generation assays, confirmatory differentiation tests, HIV RNA testing for acute infection, PrEP-related screening, and strong surveillance infrastructure. Canada emphasizes public health screening, Indigenous health equity, harm-reduction-linked testing, and access across geographically dispersed populations, while Mexico and Brazil rely on public-sector testing networks, community outreach, antenatal programs, and HIV service integration to improve earlier diagnosis.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong laboratory capacity, guideline-driven testing, blood safety systems, and expanding community-based approaches, while Russia faces a larger epidemic burden and higher need for expanded prevention-linked diagnostics and treatment monitoring. China and India represent major volume settings due to population scale, government-led testing programs, blood screening, and expanding molecular infrastructure. Japan, Australia, and South Korea offer advanced laboratory infrastructure, high regulatory standards, and growing interest in rapid, discreet, digitally connected, and patient-centered HIV testing models.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize assay accuracy, fast turnaround time, affordability, and access across clinical, community, and self-testing settings. Portfolio strategies should combine high-throughput laboratory systems, rapid tests, molecular confirmation, early infant diagnosis, viral load monitoring, CD4 testing where clinically relevant, and digital reporting tools to support diagnosis, treatment initiation, and long-term care.

Manufacturers and service providers should strengthen evidence generation, regulatory readiness, quality management, and supply continuity. Strategic partnerships with public health agencies, community organizations, procurement bodies, and reference laboratories can improve reach among high-risk and underserved populations. AI investments should focus on validated use cases such as demand planning, quality control, laboratory workflow optimization, and linkage-to-care analytics rather than replacing established diagnostic algorithms.

Research Methodology for HIV Diagnostics Analysis

This executive summary is grounded in triangulated secondary research from authoritative public health and regulatory sources, including UNAIDS, WHO, CDC, ECDC, FDA, national HIV guidelines, peer-reviewed literature, and official health ministry publications. Market interpretation is aligned with verified epidemiological indicators, testing guidance, diagnostic technology adoption, and regulatory developments.

The methodology emphasizes data validation through cross-source comparison, assessment of regional disease burden, evaluation of testing infrastructure, and review of product categories including immunoassays, rapid tests, nucleic acid testing, CD4 testing, early infant diagnosis, and viral load monitoring. Insights are presented to support strategic planning without relying on unsupported projections, market sizing, market share estimates, or unverified claims.

Conclusion: Diagnostics as the Foundation of HIV Control

HIV and AIDS diagnostics are evolving from traditional clinic-based testing toward integrated, accessible, and data-enabled systems that support prevention, treatment, and surveillance. The sector remains driven by the global need to identify undiagnosed infections, reduce late diagnosis, monitor treatment effectiveness, improve viral suppression, and close gaps across the HIV care continuum.

Organizations that combine clinically validated assays, decentralized access, regulatory discipline, supply reliability, and responsible digital innovation will be best positioned to serve health systems and patients. As countries continue pursuing HIV epidemic control, diagnostics will remain a foundational pillar of public health strategy and sustainable industry growth.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. HIV or AIDS Diagnostics Market, by Test Type

• 7.1. Antibody Tests
  • 7.1.1. ELISA/EIA
  • 7.1.2. Rapid Tests
  • 7.1.3. Western Blot Test
• 7.2. CD4 Tests
• 7.3. Viral Load Tests

8. HIV or AIDS Diagnostics Market, by Type of Product

• 8.1. Consumables & Reagents
• 8.2. Instruments & Kits
• 8.3. Software
• 8.4. Testing Services

9. HIV or AIDS Diagnostics Market, by Testing Method

• 9.1. Laboratory-Based Testing
• 9.2. Point-Of-Care Testing
• 9.3. Self-Testing

10. HIV or AIDS Diagnostics Market, by End-User

• 10.1. Blood Banks & Transfusion Centers
• 10.2. Diagnostic Centers
• 10.3. Home Care Settings
• 10.4. Hospitals & Clinics
• 10.5. Research Institutes

11. HIV or AIDS Diagnostics Market, by Application

• 11.1. Disease Progression
• 11.2. Monitoring
• 11.3. Screening

12. HIV or AIDS Diagnostics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. HIV or AIDS Diagnostics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. HIV or AIDS Diagnostics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. ACON Laboratories
• 16.3. Beckman Coulter, Inc.
• 16.4. Becton, Dickinson and Company
• 16.5. Bio-Rad Laboratories
• 16.6. bioMerieux SA
• 16.7. Chembio Diagnostics, Inc.
• 16.8. Danaher Corporation
• 16.9. DiaSorin S.p.A.
• 16.10. ELITechGroup
• 16.11. Euroimmun Medizinische Labordiagnostika AG
• 16.12. F. Hoffmann-La Roche Ltd.
• 16.13. Hologic, Inc.
• 16.14. InBios International, Inc.
• 16.15. OraSure Technologies
• 16.16. Ortho Clinical Diagnostics, Inc.
• 16.17. SD Biosensor Inc.
• 16.18. Siemens Healthineers AG
• 16.19. Thermo Fisher Scientific, Inc.
• 16.20. Trinity Biotech plc
• 16.21. Viracor Eurofins Diagnostic Services
• 16.22. Wondfo Biotech Co. Ltd.